Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
On the other hand, low HOMA-IR was associated with non-melanoma skin cancer and with the use of estrogen or estrogen-plus-progestin at baseline.Baseline characteristics by HOMA-IRLow HOMA-IR n (%)Moderate HOMA-IR n (%)High HOMA-IR n (%)P valueClinical trialsEstrogen-Alone Trial < 0.001Not randomized7832 (66.4%)1977 (16.8%)1990 (16.9%)Placebo1277 (59.9%)424 (19.9%)430 (20.2%)Treated1263 (61.4%)367 (17.9%)426 (20.7%)Estrogen + Progestin Trial < 0.001Not randomized7832 (66.4%)1977 (16.8%)1990 (16.9%)Placebo2052 (72.3%)446 (15.7%)342 (12.0%)Treated2060 (69.5%)487 (16.4%)416 (14.0%)Calcium Vitamin D Trial0.496Not randomized9579 (66.6%)2400 (16.7%)2399 (16.7%)Placebo2439 (65.9%)649 (17.5%)612 (16.5%)Treated2466 (66.5%)652 (17.6%)593 (16.0%)Dietary Modification Trial < 0.001Not randomized10,834 (69.2%)2465 (15.7%)2367 (15.1%)Placebo1506 (60.8%)503 (20.3%)466 (18.8%)Treated2144 (58.8%)733 (20.1%)771 (21.1%)DemographicsAge < 0.00150 to 593601 (62.8%)1027 (17.9%)1105 (19.3%)60 to 696707 (65.4%)1765 (17.2%)1783 (17.4%)70 to 794176 (72.0%)909 (15.7%)716 (12.3%)Ethnicity < 0.001Caucasian9007 (70.6%)1929 (15.1%)1820 (14.3%)Asian299 (67.5%)82 (18.5%)62 (14.0%)African-American3573 (58.5%)1263 (20.7%)1270 (20.8%)Hispanic1341 (66.6%)330 (16.4%)343 (17.0%)Other/unspecified254 (55.7%)95 (20.8%)107 (23.5%)Education < 0.001Less than high school4987 (60.7%)1576 (19.2%)1651 (20.1%)College5437 (67.9%)1308 (16.3%)1257 (15.7%)Higher3963 (72.8%)805 (14.8%)673 (12.4%)Type of Job < 0.001Managerial/professional5435 (70.1%)1201 (15.5%)1118 (14.4%)Technical/sales/admin3749 (65.1%)1055 (18.3%)958 (16.6%)Service/labor2576 (62.1%)761 (18.3%)812 (19.6%)Homemaker only1412 (66.3%)354 (16.6%)364 (17.1%)Lifestyle HabitsAlcohol < 0.001Never1837 (61.0%)541 (18.0%)632 (21.0%)Past drinker2795 (56.6%)1021 (20.7%)1119 (22.7%)Current drinker9721 (71.3%)2093 (15.4%)1814 (13.3%)Smoking0.006Never7554 (67.1%)1919 (17.0%)1792 (15.9%)Past smoker5562 (65.2%)1476 (17.3%)1487 (17.4%)Current smoker1166 (68.6%)259 (15.2%)274 (16.1%)Recreation Physical Activity < 0.001(MET-hour) ≥ 0 to < 2848 (62.6%)225 (16.6%)281 (20.8%) ≥ 2 to < 8702 (59.8%)223 (19.0%)249 (21.2%) ≥ 8 to < 18733 (67.6%)187 (17.3%)164 (15.1%) ≥ 183017 (76.0%)509 (12.8%)444 (11.2%)Anthropometric MeasuresBaseline Body Mass Index < 0.001(kg/m2)Normal (18.5 to 24.9)4379 (91.7%)288 (6.0%)108 (2.3%)Overweight (25.0 to 29.9)5618 (75.1%)1126 (15.1%)735 (9.8%)Obese (≥ 30.0)3847 (44.5%)2166 (25.1%)2628 (30.4%)Baseline Waist to Hip Ratio < 0.001Normal (< 0.800)6869 (84.1%)798 (9.8%)498 (6.1%)Overweight (0.800 to 0.849)3825 (66.9%)1068 (18.7%)825 (14.4%)Obese (≥ 0.850)3574 (47.1%)1792 (23.6%)2223 (29.3%)Hormone-Related FactorsEstrogen-alone < 0.001Never9915 (66.1%)2541 (16.9%)2540 (16.9%)Past2264 (64.0%)658 (18.6%)615 (17.4%)Current2295 (70.8%)502 (15.5%)445 (13.7%)Estrogen plus Progestin < 0.001Never11,966 (64.8%)3251 (17.6%)3250 (17.6%)Past1051 (71.8%)215 (14.7%)198 (13.5%)Current1461 (78.9%)235 (12.7%)156 (8.4%)Menstrual Cycle Regularity < 0.001No990 (62.5%)272 (17.2%)321 (20.3%)Yes12,069 (66.9%)3068 (17.0%)2898 (16.1%)Sometimes irregular1306 (65.4%)335 (16.8%)355 (17.8%)Age at Menopause < 0.00145 or younger4021 (62.6%)1154 (18.0%)1252 (19.5%)46 to 494419 (69.4%)1001 (15.7%)948 (14.9%)50 to 511837 (70.0%)432 (16.5%)356 (13.6%)52 or older3067 (68.7%)743 (16.6%)655 (14.7%)Parity < 0.001Never pregnant1403 (65.5%)371 (17.3%)367 (17.1%)13279 (68.6%)794 (16.6%)709 (14.8%)23339 (68.3%)806 (16.5%)746 (15.3%)32182 (65.3%)575 (17.2%)586 (17.5%)42439 (60.9%)746 (18.6%)823 (20.5%)51737 (70.7%)376 (15.3%)344 (14.0%)Hysterectomy < 0.001No8367 (69.9%)1906 (15.9%)1695 (14.2%)Yes6112 (62.3%)1793 (18.3%)1908 (19.4%)Medical HistoryDiabetes < 0.001No13,825 (69.8%)3280 (16.6%)2698 (13.6%)Yes650 (33.0%)419 (21.3%)899 (45.7%)Hypertension < 0.001No9365 (74.5%)1787 (14.2%)1422 (11.3%)Yes4990 (55.5%)1882 (20.9%)2124 (23.6%)Cardiovascular Disease < 0.001No11,382 (67.7%)2810 (16.7%)2617 (15.6%)Yes2179 (60.8%)667 (18.6%)740 (20.6%)Stroke < 0.001No14,316 (66.7%)3628 (16.9%)3512 (16.4%)Yes164 (49.8%)73 (22.2%)92 (28.0%)Liver Disease Ever0.008No14,187 (66.6%)3610 (17.0%)3500 (16.4%)Yes296 (60.4%)91 (18.6%)103 (21.0%)Bleeding Problems Ever0.504No14,142 (66.5%)3611 (17.0%)3509 (16.5%)Yes330 (64.5%)88 (17.2%)94 (18.4%)History Skin Cancer < 0.001No13,229 (65.8%)3474 (17.3%)3412 (17.0%)Yes1230 (74.8%)226 (13.7%)189 (11.5%)Rheumatoid Arthritis Ever0.010Other/do not know5874 (64.2%)1638 (17.9%)1634 (17.9%)Yes778 (60.3%)242 (18.7%)271 (21.0%)The time-to-event analytic cohort consisted of 21,789 postmenopausal women.
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Human subjects review committees at all participating sites approved WHI protocols and participants provided written informed consent.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association between baseline insulin resistance and psoriasis incidence: the Women’s Health Initiative
Study design awaiting verification · Archives of Dermatological Research · 2021
Original publication title
Association between baseline insulin resistance and psoriasis incidence: the Women’s Health Initiative
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Small-scale studies offer conflicting evidence regarding the relationship/association between psoriasis and insulin resistance by HOMA-IR (homeostasis model assessment of insulin resistance). The purpose of this study was to assess the association between baseline HOMA-IR and psoriasis incidence in a large-scale longitudinal cohort of postmenopausal women. The analysis included 21,789 postmenopausal women from the Women’s Health Initiative. Psoriasis diagnosis was defined by fee-for-service Medicare ICD-9-CM codes assigned by dermatologists or rheumatologists, and a 2-year lookback period to exclude prevalent cases. Baseline HOMA-IR was calculated using the updated HOMA2 model.
Hazard rates from the Cox regression models were stratified by age (10-year intervals), on WHI component (Clinical Trial or Observational Study), and on randomization status within each of the WHI clinical trials. The complete model also adjusted for ethnicity, waist: hip-ratio, and smoking and alcohol habits. Among participants free of psoriasis at entry, those with high baseline HOMA-IR (≥ 2) compared to low (< 1.4) had significantly higher risk for psoriasis over 21-year cumulative follow-up (HR: 1.39, 95% CI 1.08 to 1.79, P-trend: 0.011).
In postmenopausal women, higher baseline HOMA-IR levels were significantly associated with higher incidence of psoriasis over 21-year cumulative follow-up. Results from this time-to-event analysis indicate that insulin resistance can precede and is associated with an increased risk of psoriasis. Study is limited by Medicare diagnostic code accuracy and cohort age.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00403-021-02298-9.
Authors’ abstract
Small-scale studies offer conflicting evidence regarding the relationship/association between psoriasis and insulin resistance by HOMA-IR (homeostasis model assessment of insulin resistance). The purpose of this study was to assess the association between baseline HOMA-IR and psoriasis incidence in a large-scale longitudinal cohort of postmenopausal women. The analysis included 21,789 postmenopausal women from the Women’s Health Initiative. Psoriasis diagnosis was defined by fee-for-service Medicare ICD-9-CM codes assigned by dermatologists or rheumatologists, and a 2-year lookback period to exclude prevalent cases. Baseline HOMA-IR was calculated using the updated HOMA2 model.
Hazard rates from the Cox regression models were stratified by age (10-year intervals), on WHI component (Clinical Trial or Observational Study), and on randomization status within each of the WHI clinical trials. The complete model also adjusted for ethnicity, waist: hip-ratio, and smoking and alcohol habits. Among participants free of psoriasis at entry, those with high baseline HOMA-IR (≥ 2) compared to low (< 1.4) had significantly higher risk for psoriasis over 21-year cumulative follow-up (HR: 1.39, 95% CI 1.08 to 1.79, P-trend: 0.011).
In postmenopausal women, higher baseline HOMA-IR levels were significantly associated with higher incidence of psoriasis over 21-year cumulative follow-up. Results from this time-to-event analysis indicate that insulin resistance can precede and is associated with an increased risk of psoriasis. Study is limited by Medicare diagnostic code accuracy and cohort age.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00403-021-02298-9.
Publication and source details
Original title: Association between baseline insulin resistance and psoriasis incidence: the Women’s Health Initiative
Alfred A. Chan; Houmin Li; Wendy Li; Kathy Pan; Jennifer K. Yee; Rowan T. Chlebowski; Delphine J. Lee
Archives of Dermatological Research · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T11:02:34.480157+00:00
DOI: 10.1007/s00403-021-02298-9 · PMC9512862